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Cyclooxygenase (COX) contributes to cutaneous vasodilation and sweating responses; however, the mechanisms underpinning these responses remain unknown. We hypothesized that prostaglandin E1 (PGE1) and E2 (PGE2) (COX-derived vasodilator products) directly mediate cutaneous vasodilation and sweating through nitric oxide synthase (NOS)-dependent mechanisms in young adults. Furthermore, we hypothesized that this response is diminished in older adults, since aging attenuates COX-dependent cutaneous vasodilation and sweating. In 9 young (22 Ϯ 5 yr) and 10 older (61 Ϯ 6 yr) adults, cutaneous vascular conductance (CVC) and sweat rate were evaluated at four intradermal forearm skin sites receiving incremental doses (0.05, 0.5, 5, 50, 500 M each for 25 min) of PGE1 or PGE2 with and without coadministration of 10 mM N -nitro-L-arginine, a nonspecific NOS inhibitor. N -nitro-L-arginine attenuated PGE1-mediated increases in CVC at all concentrations in young adults, whereas it reduced PGE2-mediated increases in CVC at lower concentrations (0.05-0.5 M) in older adults (all P Ͻ 0.05). However, the magnitude of the PGE 1-and PGE2-mediated increases in CVC did not differ between groups (all P Ͼ 0.05). Neither PGE1 nor PGE2 increased sweat rate at any of the administered concentrations for either the young or older adults (all P Ͼ 0.05). We show that although cutaneous vascular responsiveness to PGE1 and PGE2 is similar between young and older adults, the cutaneous vasodilator response is partially mediated through NOS albeit via low-to-high concentrations of PGE1 in young adults and low concentrations of PGE2 in older adults, respectively. We also show that in both young and older adults, PGE1 and PGE2 do not increase sweat rate under normothermic conditions. aging; thermoregulation; prostanoids; EP receptor; IP receptor; cAMP; microcirculation PREVIOUS STUDIES have shown that cyclooxygenase (COX) contributes to cutaneous vasodilation (20, 33, 36) and sweating (10) , the two main avenues for heat dissipation in humans in vivo. However, the precise mechanisms mediating these responses are still unresolved. The products of COX, prostaglandin E 1 (PGE 1 ) and E 2 (PGE 2 ), can directly induce forearm vasodilation in humans in vivo (1, 47) and sweat secretion in vitro (50, 51) . Moreover, PGE 1 and PGE 2 can augment nitric oxide (NO) production as demonstrated under in vitro situations in aortic rings from mice (21) and human polymorphonuclear neutrophils (46) . Increases in NO have been shown to contribute to cutaneous vasodilation and sweating responses mediated by cholinergic agents under both normothermic resting conditions (12, 29) and those elicited by exercise-induced whole body heat stress (10, 34, 35, 57) in humans. Therefore, it is plausible that PGE 1 and PGE 2 may directly induce cutaneous vasodilation and sweating through NO synthase (NOS)-dependent mechanisms.
Aging diminishes the contribution of COX to cutaneous vasodilation (18, 20) and sweating (11) ; however, the mechanism(s) underpinning this response remains unresolved. It is plausible that aging may reduce the ability for COX to produce vasodilator prostanoids (i.e., PGE 1 and PGE 2 ). Alternatively, aging may impair the peripheral sensitivity of the end organs (i.e., skin blood vessels and sweat glands) to prostanoids. The reduced peripheral sensitivity to prostanoids is postulated to be age related as evidenced by lower forearm vasodilation responses to prostacyclin (a COX-derived prostanoid) in human adults aged 61-73 yr relative to those aged 19 -45 yr in vivo (44) . Similarly, PGE 1 -and PGE 2 -mediated cutaneous vasodilation and sweating occurring through NOS-dependent mechanisms, if any, may be diminished in older compared with young adults.
The primary objectives of this study were 1) to assess the mechanism(s) underpinning the cutaneous vasodilator and sweating responses to the administration of PGE 1 and PGE 2 , and 2) to determine whether aging may influence the pattern of these responses. We evaluated the hypothesis that in young adults, local administration of PGE 1 and PGE 2 directly induces increases in cutaneous blood flow and sweating through NOSdependent mechanisms, and that these responses are attenuated in older adults. By advancing our understanding of the role of PGE 1 and PGE 2 in the regulation of cutaneous vasodilation and sweating, we can address important knowledge gaps in the mechanism(s) underpinning the regulation of heat loss especially in the context of aging; a factor that has been shown to induce marked impairments in the body's capacity to dissipate heat (13, 26) .
MATERIALS AND METHODS

Ethical Approval
This study was approved by the University of Ottawa Health Sciences and Science Research Ethics Board, which conform to the guidelines set forth by the Declaration of Helsinki. We obtained verbal and written informed consent from all volunteers before their participation in this study.
Participants
Nine young (19 -34 yr, 4 males and 5 females) and 10 older (53-71 yr, 3 males and 7 females) habitually active (2-5 days per wk, Ն30 min of exercise per day) adults participated in one screening and one experimental session conducted on separate days. Individuals were excluded from the study if they had a history of specific medical conditions (cystic fibrosis transmembrane conductance regulator mutations, skin disorders, hypertension, heart disease, diabetes, or autonomic disorders), were taking prescription medication, were smokers, or had smoked within the last 10 years. To control for female menstrual cycles (28) , the experimental session took place during the early follicular phase (within 6 days from the beginning of menstruation) in the young adults. None of the young females were taking oral contraceptives, and all older females were postmenopausal.
During the preliminary session, body height was measured using an eye-level physician stadiometer (model 2391, Detecto Scale, Webb City, MO), and body mass was measured using a digital weight scale platform (model CBU150X, Mettler Toledo, Schwerzenbach, Switzerland) with a weighing terminal (model IND560, Mettler Toledo). The participant characteristics are presented in Table 1 , including resting blood pressures obtained before the start of the experimental session using a mercury column sphygmomanometer (Baumanometer Standby model, WA Baum, Copiague, NY).
Experimental Session
All participants were instructed to abstain from taking medications (including nonsteroidal anti-inflammatory drugs, vitamins, and minerals, and other over-the-counter medications) for at least 48 h before the experimental session. Furthermore, at least 12 h before the experimental session, participants were asked to refrain from consuming alcohol, caffeine, or performing strenuous physical activity. Participants were also restricted from consuming food 2 h before and during the experimental session. Upon arrival to the laboratory, the participants provided a urine sample to evaluate hydration status as assessed by the measurement of urine specific gravity using a handheld total solids refractometer (model TS400, Reichter, Depew, NY). Urine specific gravity evaluated before the experiment was 1.015 Ϯ 0.005 and 1.015 Ϯ 0.004 in the young and older adults, respectively, indicating that participants were euhydrated (5). Participants were then required to rest in a semirecumbent upright position on a bed in a thermoneutral environment (ambient air temperature of 27°C). During this time, at four skin sites on the anterior forearm (each separated by Յ4 cm), a 25-gauge needle was inserted into the unanesthetized skin using an aseptic technique with the entry and exit points separated by ϳ2.5 cm. A microdialysis fiber (30 kDa cutoff, 10 mm membrane) (MD2000, Bioanalytical Systems, West Lafayette, IN) was then threaded through the lumen of the needle. The needle was subsequently withdrawn leaving the fiber in the dermal layer of the dorsal forearm skin. Each fiber was connected to the outlet port of a liquid switcher (model 110, CMA Microdialysis, Kista, Sweden). At ϳ10 min after the placement of the microdialysis fibers, two of four fibers were perfused with lactated Ringer (Baxter, Deerfield, IL), whereas the other two fibers were perfused with 10 mM N -nitro-Larginine (L-NNA, Sigma-Aldrich, St. Louis, MO) dissolved in lactated Ringer to nonselectively inhibit NOS. Perfusion at each of the skin sites was maintained at a rate of 4.0 l/min using a microinfusion pump (model 4004, CMA Microdialysis, Solna, Sweden). L-NNA was continuously perfused for at least 60 min to ensure NOS blockade. The concentration of L-NNA was determined based on previous studies employing intradermal microdialysis in the human skin (8, 36) .
After the insertion of the microdialysis probes, a rest period (87 Ϯ 6 min, range: 67-119 min) was employed to ensure that the localized trauma associated with the insertion of the probe had subsided. Thereafter, baseline measurements were acquired for at least 10 min (Baseline). The infusions of PGE 1 and PGE2 (both obtained from Cayman Chemical, Ann Arbor, MI) were subsequently administrated at a rate of 4.0 l/min in an incremental manner with five different concentrations (0.05, 0.5, 5, 50, and 500 M). PGE 1 was administered to one of the lactated Ringer (PGE 1) and L-NNA sites (PGE1 ϩ L-NNA). Similarly, PGE2 was administered to the other lactated Ringer site (PGE 2) as well as to the other L-NNA site (PGE2 ϩ L-NNA). All doses of PGE1 and PGE2 infusions continued for 25 min. The five incremental concentrations of PGE 1 and PGE2 were determined in a pilot study wherein two young adults were tested. The administered PGE 1 and PGE2 solutions were dissolved in lactated Ringer with pH of 6.5. All solutions containing PGE 1, PGE2, and/or L-NNA used in the present study had similar pH levels (ϳ6 -7) as assessed by pH test paper (Hydrion pH paper, Sigma-Aldrich). A basic solution (pH Ͼ 7.4) was not used since it can degrade both PGE 1 and PGE2 to prostaglandin A and B (61) . This degradation prevents us from assessing the effects of PGE1 and PGE2 on cutaneous vasodilation and possibly sweating responses, as both prostaglandin A and B can cause vasodilation in humans in vivo (47) .
After the infusion of the final concentration of PGE1 and PGE2 (i.e., 500 M), 50 mM of sodium nitroprusside (SNP; Sigma-Aldrich) was administered at each microdialysis site at a rate of 6.0 l/min. The administration of SNP lasted for 20 -30 min, until a stable plateau of cutaneous vascular conductance (CVC) was observed over a minimum 2-min period. At this point, blood pressure was measured to quantify maximal CVC. Immediately after the maximal cutaneous vasodilation response was achieved, a higher concentration of PGE1 and PGE2 (10 mM), each dissolved in 20% of dimethyl sulfoxide (Sigma-Aldrich), was infused to the PGE1 and PGE2 sites, respectively, in two young participants. This was done to evaluate if this higher concentration of PGE1 and PGE2 would modulate sweat rate.
Measurements
Cutaneous red blood cell flux expressed in perfusion units was collected continuously at a sampling rate of 32 Hz with laser-Doppler flowmetry (PeriFlux System 5000, Perimed, Stockholm, Sweden). Integrated laser-Doppler flowmetry probes with a 7-laser array (model 413, Perimed) were placed in the center of each sweat capsule (see below for details) over each microdialysis fiber for simultaneous measurement of both local forearm sweat rate and cutaneous red blood cell flux. Manual auscultation was performed using a mercury column sphygmomanometer (Baumanometer Standby model) to obtain blood pressures every 10 -15 min. Mean arterial pressure was calculated from diastolic arterial pressure plus one-third the difference between systolic and diastolic pressures. CVC was evaluated as cutaneous red blood cell flux divided by mean arterial pressure. CVC data were presented as percentage of maximum (%max) to minimize the effect of site-to-site heterogeneity on the level of cutaneous blood flow (39) .
Sweat capsules (surface area: 1.1 cm 2 ) were placed directly over the center of each microdialysis membrane with the aid of a black mark placed at each end of the microdialysis fiber (i.e., 2 cm away from either end of the microdialysis membrane). The sweat capsules were secured to the skin with adhesive rings and topical skin glue (Collodion HV, Mavidon Medical products, Lake Worth, FL). Dry compressed air in a gas tank located within the testing room maintained at 27°C was supplied to each capsule at a rate of 0.2 l/min. The water content of the effluent air from the sweat capsule was measured with high-precision dew point mirrors (model 473, RH systems, Albuquerque, NM). Long vinyl tubes were employed for connections between the gas tank and the sweat capsule, and between the sweat capsule and the dew point mirror. Local forearm sweat rate was calculated every 5 s based on the difference in water content between influent and effluent air multiplied by the flow rate and normalized for the skin surface area under the capsule (mg·min Ϫ1 ·cm Ϫ2 ).
Data Analysis
Because we did not observe sex-related differences in the pattern of responses in cutaneous vasodilation and sweating, males and females were combined for data analysis in both groups. Furthermore, in the present study, all data from our older adults between the ages of 53 to 71 yr were combined for analysis since there were no observed age-related differences in sweating and cutaneous vasodilation responses within this group. All CVC and sweat rate values used for data analysis were obtained by averaging measurements made over the last 5 min of each stage (Baseline, 0.05, 0.5, 5, 50, and 500 M of PGE 1 or PGE2). PGE1-or PGE2-induced changes in CVC from Baseline were also evaluated as ⌬CVC at each skin site.
Statistical Analysis
Statistical analyses were performed using the software package SPSS 23 for Windows (IBM, Armonk, NY). Based on sweat rate (54) and CVC results (9) obtained in our previous works with 80% power and a significance level of 0.05, a minimum sample size was calculated. We found that the minimal sample size was n ϭ 8 for sweat rate and n ϭ 9 for CVC. CVC and sweat rate before and during PGE 1 administration were analyzed using a three-way, mixed-model, analysis of variance (ANOVA) with the factors of treatment site (two levels: PGE 1, PGE1 ϩ L-NNA), age (two levels: young, older), and stage (six levels: Baseline, 0.05, 0.5, 5, 50, or 500 M of PGE1). A two-way, mixed-model, ANOVA with the factors of treatment site (two levels: PGE1, PGE1 ϩ L-NNA) and age (two levels: young, older) was employed for ⌬CVC obtained during PGE1 administration (separately performed at each stage of 0.05, 0.5, 5, 50, or 500 M of PGE 1), as well as maximal absolute CVC (perfusion units mmHg Ϫ1 ). The data analyses detailed above were also performed for PGE2 data. When a significant interaction or main effect was detected, post hoc comparisons were carried out using Student's paired (for betweentreatment site comparison) or unpaired (for between-group comparison) two-tailed t-tests; Student's paired one-tailed t-tests corrected for multiple comparisons using a Holm Bonferroni procedure were employed to test whether sweat rates obtained during administration of each dose of PGE 1 or PGE2 were higher than that obtained at Baseline. The Kolmogorov-Smirnov test assessed the normal distribution of the data. In the instance that a normal distribution was not detected, the Wilcoxon signed-rank test was used for all pairwise comparisons and the Mann-Whitney U test was used for all betweengroup comparisons. The level of significance for all analyses was set at P Յ 0.05. All values are reported with a mean Ϯ 95% confidence interval (1.96 ϫ standard error of the mean). Figure 1 shows the time-course changes in an index of cutaneous blood flow in response to PGE 1 (Fig. 1A) and PGE 2 (Fig. 1B) obtained in a representative young subject. Cutaneous vascular responses (expressed both in CVC and ⌬CVC from Baseline) are presented in Table 2 (during Baseline) and Figs. 2 and 3 (during Baseline and PGE 1 and PGE 2 administration). There were no age-related differences in CVC and ⌬CVC measured at the Control site (all P Ͼ 0.11) throughout the protocol from Baseline to the last concentration of administered PGE 1 or PGE 2 . However, CVC at the L-NNA ϩ PGE 1 site was lower in young relative to older adults (all P Ͻ 0.05). The lower CVC response is associated with an L-NNA-mediated reduction in CVC, which occurred before and/or during the infusion of PGE 1 in the young adults only (all P Ͻ 0.05). Similarly, ⌬CVC during PGE 1 administration was lower at the L-NNA site compared with the Control site in young adults (all P Ͻ 0.05). By contrast, L-NNA coadministration resulted in a lower CVC response (including ⌬CVC) during PGE 2 administration in the older adults (all P Յ 0.05). However, this reduction was not observed in the young adults (all P Ͼ 0.08). There were no differences in maximal absolute CVC between treatment sites and groups (P Ͼ 0.18 for main effects of age 
RESULTS
Cutaneous Vascular Conductance
All values are expressed as mean Ϯ 95% confidence interval. Data from 9 young and 10 older participants are presented. PGE1 and PGE2, prostaglandin E1 and E2, respectively; L-NNA, N -nitro-L-arginine, a nonspecific nitric oxide synthase inhibitor. *PGE1 vs. PGE1 ϩ L-NNA site or PGE2 vs. PGE2 ϩ L-NNA site in young groups (P Ͻ 0.05); †Young vs. older at PGE1 ϩ L-NNA site (P Ͻ 0.05).
and treatment site and an interaction between age and treatment site) ( Table 3) .
Sweating
Sweating responses are presented in Fig. 4 . No increases in sweat rate were measured relative to Baseline at any of the administered doses of both PGE 1 and PGE 2 irrespective of treatment sites and groups (all P Ͼ 0.91). Sweat rate did not differ between treatment sites and groups throughout the protocol from Baseline to the last concentration of administered PGE 1 and PGE 2 (all P Ͼ 0.11). Furthermore, sweat rate was unaffected by the infusion of a high dose of PGE 1 and PGE 2 (10 mM) at the end of the experimental trial (as verified in two young adults).
DISCUSSION
We show for the first time that in response to a low-to-high concentration of PGE 1 , NOS contributes to cutaneous vasodilation in young adults. This is in marked contrast to the pattern of response measured in older adults wherein NOS contributes to cutaneous vasodilator responses only during administration of low concentrations of PGE 2 . However, the magnitude of increase in the PGE 1 -and PGE 2 -mediated modulation of cutaneous vasodilation did not differ between young and older adults. We also show that neither administration of PGE 1 nor PGE 2 influenced the sweating response in both young and older adults under nonheat stressed conditions.
Cutaneous Vascular Response
In accordance with previous studies (3, 15, 23), we found that in young adults, NOS contributes to resting cutaneous blood flow responses under normothermic conditions (Fig. 2, A and B, Table 2 ). However, in older adults, the NOS-mediated contributions are absent indicating that this contribution becomes diminished with aging. The abolition of a NOS-mediated influence in older adults may be associated with age- (PGE2, B) administration from 0.05 to 500 M (5 levels). Data from 9 young and 10 older participants are presented. The four intradermal microdialysis skin sites are 1) PGE1; 2) PGE1 with 10 mM L-NNA, a nitric oxide synthase inhibitor (PGE1 ϩ L-NNA); 3) PGE2; 4) PGE2 with 10 mM L-NNA (PGE2 ϩ L-NNA). Values are means Ϯ 95% confidence interval. *PGE1 vs. PGE1 ϩ L-NNA site or PGE2 vs. PGE2 ϩ L-NNA site in young groups (P Ͻ 0.05); †Young vs. older at PGE1 ϩ L-NNA site (P Ͻ 0.05). ‡PGE2 vs. PGE2 ϩ L-NNA site in older groups (P Ͻ 0.05). related increases in reactive oxygen species such as superoxide (as observed in conduit arteries of older mice in vitro) (6), which exhibits a high affinity for binding to NO, consequently reducing NO bioavailability. Similarly, ascorbate (an antioxidant)-mediated reductions in reactive oxygen species have been shown to increase NOS-dependent cutaneous vasodilation in aged human skin in vivo (19) . Previous human studies in vivo have investigated if and how COX modulates cutaneous vascular (27, 33, 37, 59 ) and sweating (8 -10) responses. However, the current study is the first to evaluate how COX-mediated products (i.e., prostanoids) modulate cutaneous vasodilation and sweating in humans in vivo. In the present study, we show that NOS contributes to PGE 1 -induced cutaneous vasodilation in young adults ( Figs. 2A and 3A) . Although it remains unclear what type of prostanoid receptors exist on the human cutaneous vessels, it is possible that this NOS-dependent cutaneous vasodilation results from the activation of prostacyclin (IP) receptors. This possibility is supported by the observation that PGE 1 can activate IP receptors as measured in human peripheral blood mononuclear cells in vitro (55) . In line with this, Nicholson et al. (44) demonstrated that prostacyclin, which activates the IP receptors, induces an increase in forearm vasodilation that is partly mediated through NOS-dependent mechanisms in young human adults in vivo. Moreover, a study by Nasrallah et al. (43) showed, using in vitro model of rabbit's cortical collecting duct, that the activation of IP receptors could increase intracellular Ca 2ϩ . As such, the NOS contribution to PGE 1 -induced cutaneous vasodilation may occur via Ca 2ϩ -dependent mechanisms as an elevation in intracellular Ca 2ϩ has been shown to activate NOS in the endothelial cells of porcine aorta in vitro (4) .
Cutaneous vascular conductance (%max)
In contrast to the influence of NOS on PGE 1 , we showed that NOS does not contribute to the PGE 2 -induced increase in cutaneous vasodilation in young adults (Figs. 2B and 3B ) demonstrating that the mechanisms underpinning the PGEmediated modulation of cutaneous vasodilation differs as a function of the type of prostaglandin (i.e., PGE 1 and PGE 2 ). In line with the evidence from cultured hamster ovary cells in vitro (42) , it is possible that the disparate responses may be related to the fact that 1) PGE 1 , but not PGE 2 , activates IP receptors; 2) PGE 2 , but not PGE 1 , activates prostaglandin F (FP) receptors; and/or 3) PGE 2 has a higher affinity for the EP1 receptor (one of the prostaglandin E receptor) compared with PGE 1 .
In older adults, the contribution of NOS to PGE 1 -induced cutaneous vasodilation is diminished ( Figs. 2A and 3A) relative to the response measured in young adults. Given IP receptor may underlie the PGE 1 -induced NOS-dependent cutaneous vasodilation as discussed above, the diminished NOS contribution could be due to age-related reduction in IP receptors sensitivity, as was observed in human forearm circulation in vivo (44) . Noteworthily, we show that NOS contributes to PGE 2 -induced cutaneous vasodilation only in older adults (Figs. 2B and 3B) . At the moment, we are not aware of any plausible explanation for this response and future studies are required to elucidate the underlying mechanisms mediating this response.
Previous in vivo human studies reported that aging attenuates COX-dependent cutaneous vasodilation during administration of acetylcholine (20) and application of whole body heat stress (18) . In relation to these responses, we found that similar cutaneous blood flow responses to PGE 1 and PGE 2 occur between young and older adults (Figs. 2 and 3) , suggesting that aging does not impair cutaneous vascular responsiveness to prostanoids. Therefore, the previously observed agerelated attenuation of COX-mediated cutaneous vasodilation All values are expressed as means Ϯ 95% confidence interval. Data from 9 young and 10 older participants are presented (in perfusion units mmHg Ϫ1 ). P Ͼ 0.18 for main effects of age and treatment site, and an interaction between age and treatment site. Values are means Ϯ 95% confidence interval. Any dose of PGE1 or PGE2 did not increase sweat rate from Baseline (all P Ͼ 0.91). No age-associated and between-site differences in sweat rate were observed at Baseline and each dose of PGE1 or PGE2 (P Ͼ 0.11 for main effects of age and treatment site as well as an interaction between age and treatment site). (18, 20) may denote a reduction in the bioavailability of COX-derived vasodilator prostaglandins in human skin. We show that in both young and older adults, the PGE 1 -and PGE 2 -induced increases in cutaneous blood flow were still observed even in the presence of NOS inhibition. This suggests the possible involvement of non-NOS mechanisms, which may be associated with the cAMP signaling cascade. In this regard, using chondrocytes isolated from chicks in vitro, O'Keefe and colleagues (45) showed that both PGE 1 and PGE 2 can increase cAMP. If this increase occurs in the vascular smooth muscle cells, it would result in vasorelaxation. Alternatively, the activation of potassium channels may also contribute to this response. Both calcium-activated potassium (K Ca ) channels (2, 3, 31) and ATP-sensitive potassium (K ATP ) channels (17) can influence the cutaneous vasodilator response by hyperpolarizing vascular smooth muscle cells in the human skin under in vivo situations. Importantly, PGE 1 and PGE 2 can activate large-conductance calcium-activated potassium (BK Ca ) channels in human corporal or coronary artery smooth muscle cells in vitro (30, 60) and K ATP channels in rat thoracic aortic rings (7). Finally, PGE 2 can cause axon-reflex-mediated cutaneous vasodilation in humans in vivo (48) , which may also be involved in non-NOS-dependent cutaneous vasodilation during PGE 2 administration. Indeed, an in vivo human study shows that most of the axon-reflex-mediated cutaneous vasodilation can occur independently of NOS (40) .These potential mechanisms warrant further investigation.
McCord et al. (33) demonstrated that COX contributes to cutaneous vasodilation during passive heating at rest in young adults in vivo. There are some possible mechanisms mediating this COX-dependent cutaneous vasodilation. A rise in core and/or skin temperatures associated with whole body heat stress would increase the release of neurotransmitters from cholinergic nerves, mediating cutaneous vasodilation in humans in vivo (22, 24) . Acetylcholine, a cholinergic neurotransmitter, appears to mediate the aforementioned COX-dependent cutaneous vasodilation during passive heat stress at rest. This is supported by previous studies that have consistently shown that intradermal administration of acetylcholine achieved via microdialysis induces cutaneous vasodilation that is greatly due to COX activation (12, 20, 25, 36) . Moreover, the COX-dependent cutaneous vasodilation during heat stress occurs independently of NOS (33) . Given that PGE 2 , but not PGE 1 , induces NOS-independent cutaneous vasodilation in young adults in the current study (Figs. 2B and 3B) , PGE 2 may be involved in the COX-dependent cutaneous vasodilation during passive heating at rest (33) . Additionally, COX-induced increases in CVC during passive heating at rest was reported to be ϳ16%max (33), which is equivalent to the increase in CVC induced by 0.5 M PGE 2 (Fig. 3B) . Therefore, cutaneous vasodilation mediated by 0.5 M PGE 2 may represent COXdependent cutaneous vasodilation occurring during passive heat stress at rest in young adults.
Sweating
We show that the infusion of PGE 1 and PGE 2 had no effect on sweating (Fig. 4) , which is in stark contrast to in vitro studies, which reported that both PGE 1 and PGE 2 can directly increase sweat secretion (50, 51) . The underlying reasons for the disparity between in vivo and in vitro observations remain unclear. However, sympathetic nerves, sensory nerves, vessels, adipose tissues, and keratinocytes surround sweat glands under in vivo conditions, which differ from in vitro conditions wherein adjacent tissues are not present. Therefore, the surrounding tissues may directly or indirectly participate in the sweat secretion process in vivo. In line with this, all four prostaglandin E (EP) receptors (EP1, EP2, EP3, EP4) are expressed in keratinocytes within the human skin (49) . Future studies elucidating if other surrounding tissues (sympathetic nerves, sensory nerves, vessels, and adipose tissues) that possess EP receptors would provide more insight into whether and how PGE 1 and PGE 2 modulate sweating in vivo. Also, differential mechanisms between in vivo and in vitro are not unique to PGE-mediated responses. In fact, in our previous work we showed comparable results for ATP whereby no effect of ATP was measured during infusion in human skin in vivo (8) , although increases in sweating were recorded during in vitro work (52) .
We previously reported that COX contributes to the sweating response in young adults exercising in the heat (10). Although we are not aware of any evidence showing the presence of prostanoid receptors in the human sweat gland, a study shows that COX is present (41) ; the latter of which is consistent with the observed COX-dependent sweating (10) . Given that PGE 1 and PGE 2 did not elicit sweating in human skin under normothermic conditions (Fig. 4) , the COX-dependent increase in sweating observed during exercise in the heat (10) is likely the result of an augmentation in the signaling cascade mediated via muscarinic receptor activation, which is a key mechanism that was previously identified in the regulation of sweating in vivo (24, 32, 38, 53) . However, we also showed that under normothermic resting conditions in vivo, COX inhibition does not modulate muscarinic receptor activation-induced sweating (9) . Thus it is plausible that increases in body temperature (i.e., skin and/or core temperature) are necessary to observe COX-dependent modulation of sweating responses. This is supported by our previous observation that a COX-dependent increase in sweating occurred with marked increases in body temperature induced by exercise in the heat (10) . Mechanistically, it has been shown that local heating of skin can activate the heat shock protein 90 in the human skin in vivo (58) , which can in turn activate COX, leading to an increase in the production of prostanoids, as evidenced by rat fibroblastic cells in vitro (56) .
Considerations
It is important to consider that there are several types of prostaglandin receptors, which include, but are not limited to, EP (EP1, EP2, EP3, EP4), IP, and FP receptors. PGE 1 (42) . Therefore, it is uncertain as to which prostaglandin receptor(s) is(are) responsible for the observed cutaneous vasodilation responses associated with PGE 1 and PGE 2 . Future studies investigating which prostanoid receptors exist in human skin vessels (endothelial and/or vascular smooth muscle cells) would provide some insight into addressing this knowledge gap. However, elucidating information about prostanoid recep-tor is particularly challenging in humans in vivo given the significant safety concerns associated with the infusion of pharmacological agents (both agonist and/or antagonist) that would be required to assess the specific prostanoid receptors, which to date have yet to be tested in humans in vivo. However, prostacyclin or its analogue, which activates IP receptors, has been widely used in humans in vivo for clinical (i.e., pulmonary arterial hypertension) and experimental (14, 44) purposes. If the observed responses with PGE 1 in the present study are primarily due to activation of IP receptors as discussed above, administration of prostacyclin or its analogue, therefore, should replicate cutaneous vasodilation responses induced by PGE 1 . Thus at a minimum, advancing our understanding of the role of IP receptors in PGE 1 -induced cutaneous vasodilation is an important direction to take in future studies.
It is also important to consider that the effect of NOS on cutaneous vasodilation in response to PGE 1 and PGE 2 differs slightly depending on whether absolute CVC or ⌬CVC is employed. Using ⌬CVC from Baseline may be a more appropriate approach as CVC during Baseline differs between sites. When ⌬CVC is used, the effect of NOS on cutaneous vasodilation is limited to lower concentrations of PGE 1 and PGE 2 ( Fig. 3) relative to absolute CVC (Fig. 2) . Nevertheless, the between-group differences in NOS contribution to cutaneous vasodilation during PGE 1 and PGE 2 administrations are clearly depicted using both approaches.
Prostaglandins can cause inflammatory responses in the skin (16) . Therefore, the increase in cutaneous blood flow in response to the administration of PGE 1 and PGE 2 observed in the present study may reflect an inflammatory response, rather than PGE 1 -and PGE 2 -induced direct activation of cutaneous vessels.
We did not precisely measure pH in the pharmacological solutions used for the present study. Therefore, we do not know how much pH differed between solutions and the extent to which the difference in pH influenced our results.
Perspectives and Significance
Our results show that both PGE 1 and PGE 2 can induce substantial cutaneous vasodilation in older adults to a similar degree as observed in young adults. Heat dissipation in older adults is normally attenuated (13, 26) . Thus interventions that increase vasodilator prostanoids (e.g., PGE 1 and PGE 2 ) may augment heat loss response of cutaneous vasodilation and thus heat transfer from the body core to the surface of the skin, mitigating or reversing the age-related impairments in the physiological capacity of the body to dissipate heat. Direct evaluation of this possibility during challenges to human heat balance associated with elevations in environmental heat load, metabolic rate during physical activity in the heat, and the combination of the two is required in future studies.
In conclusion, we show that NOS partially contributes to a prostaglandin-mediated increase in cutaneous vasodilation in young and older adults. However, the response is dependent on the type of prostaglandin (i.e., PGE 1 and PGE 2 ) such that NOS partly contributes to cutaneous vasodilation in response to low-to-high concentrations of PGE 1 (0.05-50 M) in young adults, whereas this contribution is only observed in response to lower concentrations of PGE 2 (0.05-0.5 M) in older adults. Furthermore, cutaneous vasodilation responsiveness to PGE 1 and PGE 2 is similar between young and older adults at all concentrations tested. Finally, we show that for all concentrations of PGE 1 and PGE 2 employed in the present study, there is no influence on the sweating response in both young and older adults under normothermic conditions. This study advances our physiological knowledge associated with COXdependent modulation of cutaneous vasodilation and sweating, and provides valuable insights into how aging modulates these mechanisms.
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